Navigation Links
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
Date:10/29/2010

ficantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days.  NUEDEXTA is contraindicated in patients with a known hypersensitivity to its components.

NUEDEXTA may cause serious side effects, including possible changes in heart rhythm.  NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, in patients with heart failure as well as patients with, or at risk of, complete atrioventricular (AV) block, unless the patient has an implanted pacemaker.  

NUEDEXTA causes dose-dependent QTc prolongation.  When initiating NUEDEXTA in patients at risk of QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, weakness, swelling of feet and ankles, urinary tract infection, flu, elevated liver enzymes, and flatulence.

NUEDEXTA may cause dizziness.  Precautions to reduce the risk of falls should be taken, particularly for patients with motor impairment affecting gait or a history of falls.

Patients should take NUEDEXTA exactly as prescribed.  Patients should not take more than 2 capsules in a 24-hour per
'/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... of units of common stock and warrants at a ... $20 million, prior to deducting underwriting discounts and commissions ... and warrants are immediately separable and will be issued ... begin trading on The NASDAQ Stock Market under the ...
(Date:8/21/2014)... AUSTIN, Texas , Aug. 21, 2014 /PRNewswire/ ... IT services company, announced today that it has ... Records (EMR) solution for Plastic Surgery and Dermatology ... provide even more value to healthcare practices using ... CEO of eRelevance Corporation. "Using information from the ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... in Brazil and ... guidelines and commonly prescribe long-acting beta-agonist (LABA)- and ... do so within current severe cost/coverage constraints. Therefore, ... are expected to launch in these countries—which will ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
(Date:8/23/2014)... 23, 2014 A team of New York ... longer when preceded by surgery and delivered by an experienced ... new study. Click here to read it now . ... cases of mesothelioma patients who underwent hemithoracic (one ... dose to the shape of a tumor. Patients who ...
(Date:8/23/2014)... 23, 2014 GBI Research, the leading ... Care Therapeutics in Major Developed Markets to 2020 - ... Drive Market”, which provides in-depth analysis of the critical ... Spain, Japan and Canada. The report provides an estimation ... to 2020. It covers critical care indications that are ...
(Date:8/23/2014)... Young adults in Athens, GA who find that they ... the phone and call the new helpline which can offer support ... , Troubled Teen Athens is a wonderful resource for an adolescent ... necessary steps to end substance abuse once and for all. When ... friends or peers when really they should put their faith in ...
(Date:8/23/2014)... NC (PRWEB) August 23, 2014 Teen substance ... young people in Holly Springs, NC. Countless adolescents throughout North ... regular basis. Unfortunately, many never receive professional rehab due ... adults on where to get help. Troubled Teens Holly Springs ... the lives of local teenage alcohol abusers in ...
(Date:8/22/2014)... 2014 2014 Deep Research Report ... and in-depth research report on the Glucose Meter ... including Glucose Meter definition, classification, application, and industry ... research covers the international market analysis, including domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Medicine News(10 mins):Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3
... IRVINE, Calif., June 26 ISTA Pharmaceuticals, Inc. (Nasdaq: ... Ophthalmic Drugs Advisory Committee appointed by the U.S. Food ... (bepotastine besilate ophthalmic solution) 1.5% as an eye drop ... The Committee voted unanimously 7 to 0 in favor ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ), ... information in regards to our financial position in light of ... to the FDA action are currently being identified. The early ... $15 to $20 million. , , The products subject ...
... announced today that it will hold its 2009 Annual General ... Meeting of Shareholders (the "Special Meeting") on August 5, 2009. ... asked to vote in favor of certain matters related to ... Subject to shareholder approval and the approval of the ...
... , CASTRES, France, June ... Committee for Medicinal Products for Human Use,(CHMP), the ... has issued a positive opinion supporting approval and ... monotherapy in metastatic,treatment of bladder cancer (advanced or ...
... June 26 Today Sentry Data Systems, Inc. announced ... Pharmacy and Revenue Cycle Management application. Claims Guardian ... their bills for unusual, missing, or errant charges that ... , "We believe that automatically matching actual procurement ...
... Healthcare ... the second straight year. The list is sponsored by the Greater Omaha Chamber of Commerce and ... , ... Healthcare staffing company Medical Solutions has landed on the Best Places to ...
Cached Medicine News:Health News:Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen 2Health News:Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen 3Health News:Sentry Data Systems Announces Claims Guardian(TM) 2Health News:Sentry Data Systems Announces Claims Guardian(TM) 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: